{"product_id":"scottsdale-interventional-forum-sif-2025","title":"Scottsdale Interventional Forum (SIF) 2025","description":"\u003cdiv id=\"bylineInfo\" class=\"a-section a-spacing-micro bylineHidden feature\"\u003e\r\n\u003cdiv id=\"bylineInfo\" class=\"a-section a-spacing-micro bylineHidden feature\"\u003e\r\n\u003cdiv class=\"elementor-widget-container\"\u003e\r\n\r\nVideos Only\r\n\u003cp data-start=\"39\" data-end=\"277\"\u003e\u003cstrong data-start=\"39\" data-end=\"51\"\u003eOverview\u003c\/strong\u003e\u003cbr data-start=\"51\" data-end=\"54\"\u003eScottsdale Interventional Forum (SIF) 2025 This symposium is designed to equip participants with the practical skills needed to enhance bedside patient management, apply innovative therapies effectively, and improve outcomes for patients with cardiovascular disease.\u003c\/p\u003e\r\n\u003cp data-start=\"279\" data-end=\"540\"\u003e\u003cstrong data-start=\"279\" data-end=\"298\"\u003eTarget Audience\u003c\/strong\u003e\u003cbr data-start=\"298\" data-end=\"301\"\u003eThis activity is intended for physicians, nurses, and allied health professionals seeking a comprehensive, up-to-date review of disease mechanisms, diagnostic imaging, and expert management strategies for advanced cardiovascular disorders.\u003c\/p\u003e\r\n\u003cp data-start=\"542\" data-end=\"628\"\u003e\u003cstrong data-start=\"542\" data-end=\"565\"\u003eLearning Objectives\u003c\/strong\u003e\u003cbr data-start=\"565\" data-end=\"568\"\u003eBy the end of this activity, participants should be able to:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"630\" data-end=\"2169\"\u003e\r\n \t\u003cli data-section-id=\"1b3c95x\" data-start=\"630\" data-end=\"738\"\u003eExplain the role of mechanical circulatory support in patients undergoing complex coronary intervention.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ep0vbn\" data-start=\"739\" data-end=\"816\"\u003eDiscuss novel stent platforms and the regulatory pathway to FDA approval.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"a0p1y4\" data-start=\"817\" data-end=\"939\"\u003eDevelop a practical understanding of newer methods for plaque and calcium modification in coronary disease management.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1a3011k\" data-start=\"940\" data-end=\"1058\"\u003eCompare surgical and percutaneous revascularization approaches in diabetic patients with complex coronary anatomy.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"6ievsd\" data-start=\"1059\" data-end=\"1235\"\u003eDiscuss the role of advanced imaging in cardiovascular disease management, including noninvasive imaging and high-resolution invasive coronary imaging such as OCT and IVUS.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1mvap6t\" data-start=\"1236\" data-end=\"1417\"\u003eDescribe the emerging role of mechanical left atrial appendage therapy, novel cerebral embolic protection devices, and adjunctive devices in structural heart disease management.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1kzgb4g\" data-start=\"1418\" data-end=\"1523\"\u003eApply knowledge of radial-based and alternative vascular access approaches in cardiovascular therapy.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1kvo9fu\" data-start=\"1524\" data-end=\"1652\"\u003eDefine the role of transcatheter and surgical therapies for patients with advanced aortic stenosis and aortic insufficiency.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"4k8jwe\" data-start=\"1653\" data-end=\"1777\"\u003eDiscuss the role of transcatheter aortic valve replacement (TAVR) in patients with symptomatic moderate aortic stenosis.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"e6xysr\" data-start=\"1778\" data-end=\"1869\"\u003eDescribe catheter-based therapies for degenerative and functional mitral valve disease.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"uln7g2\" data-start=\"1870\" data-end=\"1941\"\u003eDefine emerging therapies for tricuspid and pulmonic valve disease.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"16wicbb\" data-start=\"1942\" data-end=\"2083\"\u003eReview the most relevant clinical trials in coronary and structural heart disease that are shaping the near future of patient management.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"3a7rml\" data-start=\"2084\" data-end=\"2169\"\u003eReview the most important recent trials in antiplatelet and antithrombotic therapy.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n \r\n\u003ctable\u003e\r\n\u003cthead\u003e\r\n\u003ctr\u003e\r\n\u003cth\u003eS. No.\u003c\/th\u003e\r\n\u003cth\u003eTitle\u003c\/th\u003e\r\n\u003cth\u003eRun Time\u003c\/th\u003e\r\n\u003c\/tr\u003e\r\n\u003c\/thead\u003e\r\n\u003ctbody\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e1\u003c\/td\u003e\r\n\u003ctd\u003eRCA ISR Management: Stent Boost and IVUS Inform DES Over DCB in Elderly Patient\u003c\/td\u003e\r\n\u003ctd\u003e43:51\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e2\u003c\/td\u003e\r\n\u003ctd\u003eSevere Valvular and Left Main CAD in Frail Patient: DK Crush PCI Strategy and Impella Support\u003c\/td\u003e\r\n\u003ctd\u003e43:52\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e3\u003c\/td\u003e\r\n\u003ctd\u003eAortic Valve-in-Valve in Lotus Prosthesis: Technical Challenges and Key Lessons\u003c\/td\u003e\r\n\u003ctd\u003e53:48\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e4\u003c\/td\u003e\r\n\u003ctd\u003eChronic Total Occlusion in RCA With Severe Obesity: Retrograde PCI Strategy and IVUS Guidance\u003c\/td\u003e\r\n\u003ctd\u003e36:34\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e5\u003c\/td\u003e\r\n\u003ctd\u003eValve-in-Valve in Bicuspid AVR With Dacron Graft: Managing Fracture Limitations\u003c\/td\u003e\r\n\u003ctd\u003e22:59\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e6\u003c\/td\u003e\r\n\u003ctd\u003eCTO in RCA With Persistent Angina: Dual Guide Approach, IVUS Imaging, and Stenting\u003c\/td\u003e\r\n\u003ctd\u003e39:37\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e7\u003c\/td\u003e\r\n\u003ctd\u003ePresentation of a Case: Concomitant AF Ablation and LAA Occlusion\u003c\/td\u003e\r\n\u003ctd\u003e36:38\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e8\u003c\/td\u003e\r\n\u003ctd\u003eSevere MR in a 71-Year-Old: Valve-in-Valve-in-Ring Approach and Deployment Challenges\u003c\/td\u003e\r\n\u003ctd\u003e15:07\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e9\u003c\/td\u003e\r\n\u003ctd\u003eWomen’s Heart Disease: Key Symptom Patterns and Early Detection\u003c\/td\u003e\r\n\u003ctd\u003e07:51\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e10\u003c\/td\u003e\r\n\u003ctd\u003eExamples of Escalating MCS in STEMI\u003c\/td\u003e\r\n\u003ctd\u003e10:35\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e11\u003c\/td\u003e\r\n\u003ctd\u003eMechanical Complications of MI with Cardiogenic Shock: MitraClip Rescue\u003c\/td\u003e\r\n\u003ctd\u003e08:58\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e12\u003c\/td\u003e\r\n\u003ctd\u003eVascular Access Challenges with MCS\u003c\/td\u003e\r\n\u003ctd\u003e10:00\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e13\u003c\/td\u003e\r\n\u003ctd\u003eCut, Laser, Drill, and Shock\u003c\/td\u003e\r\n\u003ctd\u003e15:28\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e14\u003c\/td\u003e\r\n\u003ctd\u003eMassive Coronary Thrombosis- Treatment Algorithm and Creative Approaches\u003c\/td\u003e\r\n\u003ctd\u003e16:18\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e15\u003c\/td\u003e\r\n\u003ctd\u003eThe Most Difficult Bifurcations- A Step-by-Step Algorithm\u003c\/td\u003e\r\n\u003ctd\u003e15:32\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e16\u003c\/td\u003e\r\n\u003ctd\u003eApproaches to Treating Complex Vein Graft Lesions (and the Native Vessels They Supply)\u003c\/td\u003e\r\n\u003ctd\u003e14:57\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e17\u003c\/td\u003e\r\n\u003ctd\u003eMitral Transcatheter Edge-to-Edge Repair and Mandatory Mechanical Circulatory Support in Patients with Structural Shock\u003c\/td\u003e\r\n\u003ctd\u003e13:19\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e18\u003c\/td\u003e\r\n\u003ctd\u003eNovel Use of MitraClip to Treat Aortic Regurgitation\u003c\/td\u003e\r\n\u003ctd\u003e08:52\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e19\u003c\/td\u003e\r\n\u003ctd\u003eIntravascular Imaging is Now Class 1A in the European Guidelines: How Should US Interventionalists Respond?\u003c\/td\u003e\r\n\u003ctd\u003e22:43\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e20\u003c\/td\u003e\r\n\u003ctd\u003eLeaflet and Septal Modification during VIV TMVR: Rationale, Tips, and Tricks\u003c\/td\u003e\r\n\u003ctd\u003e15:28\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e21\u003c\/td\u003e\r\n\u003ctd\u003ePatient Selectiong for Tricuspid Therapies\u003c\/td\u003e\r\n\u003ctd\u003e09:35\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e22\u003c\/td\u003e\r\n\u003ctd\u003eOptimal TEE and 3D-ICE for Efficient and Effective T-TEER and TTVR\u003c\/td\u003e\r\n\u003ctd\u003e11:00\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e23\u003c\/td\u003e\r\n\u003ctd\u003eTranscatheter Mitral and Tricuspid Valve in Valve Best Practices\u003c\/td\u003e\r\n\u003ctd\u003e10:57\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e24\u003c\/td\u003e\r\n\u003ctd\u003eThe Next Pillar of Heart Failure Management – the GLP-1 Agonist Phenomenon\u003c\/td\u003e\r\n\u003ctd\u003e13:51\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e25\u003c\/td\u003e\r\n\u003ctd\u003eAortic Stenosis and Coronary Artery Disease: A Case Presentation\u003c\/td\u003e\r\n\u003ctd\u003e11:07\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e26\u003c\/td\u003e\r\n\u003ctd\u003eCoronary Evaluation and Stenting Pre-TAVR: Neither Cath nor PCI Frequently Necessary\u003c\/td\u003e\r\n\u003ctd\u003e08:37\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e27\u003c\/td\u003e\r\n\u003ctd\u003eEcho Gradients Are Flawed: All BE and SE Valves Do Well!\u003c\/td\u003e\r\n\u003ctd\u003e08:26\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e28\u003c\/td\u003e\r\n\u003ctd\u003eThe Transcatheter Valve Journey: Present and Future\u003c\/td\u003e\r\n\u003ctd\u003e12:56\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e29\u003c\/td\u003e\r\n\u003ctd\u003eTAV-in-SAV and TAV-in-TAV: ABCDs of the Pre-Procedural Evaluation\u003c\/td\u003e\r\n\u003ctd\u003e13:01\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e30\u003c\/td\u003e\r\n\u003ctd\u003ePre TAVR: Cath and Aggressive PCI for All?\u003c\/td\u003e\r\n\u003ctd\u003e11:59\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e31\u003c\/td\u003e\r\n\u003ctd\u003eThe Data Are Clear: Self-Expanding Superior in Smaller Valves\u003c\/td\u003e\r\n\u003ctd\u003e11:35\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e32\u003c\/td\u003e\r\n\u003ctd\u003eCatheter Based Treatment for Valvular Heart Disease\u003c\/td\u003e\r\n\u003ctd\u003e03:44\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e33\u003c\/td\u003e\r\n\u003ctd\u003eAdvances in Coronary Artery Disease Management\u003c\/td\u003e\r\n\u003ctd\u003e07:28\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e34\u003c\/td\u003e\r\n\u003ctd\u003eThe Growing Field of Heart Failure Management\u003c\/td\u003e\r\n\u003ctd\u003e10:49\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e35\u003c\/td\u003e\r\n\u003ctd\u003eEVOQUE Tricuspid Valve Replacement\u003c\/td\u003e\r\n\u003ctd\u003e10:38\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e36\u003c\/td\u003e\r\n\u003ctd\u003eStrategies to Prevent Heart Disease\u003c\/td\u003e\r\n\u003ctd\u003e05:45\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e37\u003c\/td\u003e\r\n\u003ctd\u003eManaging Stable CAD in Severe Aortic Stenosis: Insights from NOTION and PCI Strategies\u003c\/td\u003e\r\n\u003ctd\u003e12:04\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e38\u003c\/td\u003e\r\n\u003ctd\u003eMean Gradient with TEER: Why Higher Gradients Should be Tolerated\u003c\/td\u003e\r\n\u003ctd\u003e10:37\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e39\u003c\/td\u003e\r\n\u003ctd\u003eOptimal Pharmacologic Management Following LAAO\u003c\/td\u003e\r\n\u003ctd\u003e09:29\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e40\u003c\/td\u003e\r\n\u003ctd\u003eLeft Atrial Appendage Occlusion: Current Advances, Remaining Challenges\u003c\/td\u003e\r\n\u003ctd\u003e10:15\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e41\u003c\/td\u003e\r\n\u003ctd\u003eM-TEER for Functional MR\u003c\/td\u003e\r\n\u003ctd\u003e13:59\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e42\u003c\/td\u003e\r\n\u003ctd\u003ePutting LAAO Clinical Trials in Perspective\u003c\/td\u003e\r\n\u003ctd\u003e10:34\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e43\u003c\/td\u003e\r\n\u003ctd\u003eHow to Treat This 75-Year-Old with Severe Degenerative MR\u003c\/td\u003e\r\n\u003ctd\u003e02:10\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e44\u003c\/td\u003e\r\n\u003ctd\u003eCatheter-Based Therapies for Managing Aortic Insufficiencies\u003c\/td\u003e\r\n\u003ctd\u003e22:27\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e45\u003c\/td\u003e\r\n\u003ctd\u003eSpare the Blade – M-TEER Today!\u003c\/td\u003e\r\n\u003ctd\u003e04:50\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e46\u003c\/td\u003e\r\n\u003ctd\u003eThe Data Are Favorable, but Can T-TEER Be Democratized?\u003c\/td\u003e\r\n\u003ctd\u003e12:37\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e47\u003c\/td\u003e\r\n\u003ctd\u003eMitral Debate – No Way – Surgical Repair Rules Today!\u003c\/td\u003e\r\n\u003ctd\u003e11:58\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e48\u003c\/td\u003e\r\n\u003ctd\u003eUnderstanding FDA T-TEER Trials: Are There Enough Pros?\u003c\/td\u003e\r\n\u003ctd\u003e16:03\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e49\u003c\/td\u003e\r\n\u003ctd\u003eThe Role of Transcatheter Tricuspid Valve Replacement: Unsuccessful TTEER with Giant Coaptaion Gap\u003c\/td\u003e\r\n\u003ctd\u003e10:27\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e50\u003c\/td\u003e\r\n\u003ctd\u003eCT Guidance in TMVR: Lessons Learned and Evolving Imaging Protocols\u003c\/td\u003e\r\n\u003ctd\u003e13:14\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e51\u003c\/td\u003e\r\n\u003ctd\u003eTricuspid Regurgitation Impact on TAVR and M-TEER\u003c\/td\u003e\r\n\u003ctd\u003e10:35\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e52\u003c\/td\u003e\r\n\u003ctd\u003eTranscatheter Repair versus Mitral Valve Surgery for Secondary Mitral Regurgitation – Challenges in Trial Design and Interpretation of Outcomes\u003c\/td\u003e\r\n\u003ctd\u003e10:00\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e53\u003c\/td\u003e\r\n\u003ctd\u003eShould There Be Sex-Based Considerations in the Care of the AS Patient?\u003c\/td\u003e\r\n\u003ctd\u003e13:11\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e54\u003c\/td\u003e\r\n\u003ctd\u003eWill T-TEER Evolve Similar to M-TEER: an Operator’s Perpsective\u003c\/td\u003e\r\n\u003ctd\u003e11:27\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e55\u003c\/td\u003e\r\n\u003ctd\u003eUpstream Treatment of AS: Early TAVR, Evolved, TAVR Unload\u003c\/td\u003e\r\n\u003ctd\u003e19:37\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e56\u003c\/td\u003e\r\n\u003ctd\u003eBack to the Basics: Are Exercise Right Heart Catheterizations Mandatory?\u003c\/td\u003e\r\n\u003ctd\u003e05:37\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e57\u003c\/td\u003e\r\n\u003ctd\u003eCVD Jeopardy: Cath Lab \u0026amp; ICU Essentials – Arrhythmias, Shock, and Dissection Anticoagulation Pitfalls\u003c\/td\u003e\r\n\u003ctd\u003e17:30\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e58\u003c\/td\u003e\r\n\u003ctd\u003eThe Evolution of HFrEF Therapies\u003c\/td\u003e\r\n\u003ctd\u003e13:52\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e59\u003c\/td\u003e\r\n\u003ctd\u003eThe Emerging Role of Transcatheter Shunts\u003c\/td\u003e\r\n\u003ctd\u003e10:01\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e60\u003c\/td\u003e\r\n\u003ctd\u003eEvidence-Based Interventions Targeting Valvular Heart Disease in Heart Failure\u003c\/td\u003e\r\n\u003ctd\u003e15:13\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e61\u003c\/td\u003e\r\n\u003ctd\u003eModulHeart, Aortix and the Novel Support Devices for Heart Management\u003c\/td\u003e\r\n\u003ctd\u003e15:08\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e62\u003c\/td\u003e\r\n\u003ctd\u003eMea Culpa, Mea Culpa, Mea Maxima Culpa – STEMI Management\u003c\/td\u003e\r\n\u003ctd\u003e13:11\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e63\u003c\/td\u003e\r\n\u003ctd\u003eLeft Atrial–Coronary Sinus Shunt Case: Salvaging a Disaster\u003c\/td\u003e\r\n\u003ctd\u003e11:50\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e64\u003c\/td\u003e\r\n\u003ctd\u003eThe Heartbreak of Substance Use\u003c\/td\u003e\r\n\u003ctd\u003e15:23\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e65\u003c\/td\u003e\r\n\u003ctd\u003eContemporary Management of STEMI\/SHOCK\u003c\/td\u003e\r\n\u003ctd\u003e14:35\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e66\u003c\/td\u003e\r\n\u003ctd\u003eCardiac Biomarkers in Acute and Chronic Care\u003c\/td\u003e\r\n\u003ctd\u003e13:17\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e67\u003c\/td\u003e\r\n\u003ctd\u003eSpontaneous Coronary Artery Dissection: Women \u0026amp; Heart Disease\u003c\/td\u003e\r\n\u003ctd\u003e14:18\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e68\u003c\/td\u003e\r\n\u003ctd\u003eEquipoise – What’s That – We Did That Study Already\u003c\/td\u003e\r\n\u003ctd\u003e11:07\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e69\u003c\/td\u003e\r\n\u003ctd\u003eStructural Heart Disease – Evaluation, Management and Postop Care\u003c\/td\u003e\r\n\u003ctd\u003e15:11\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e70\u003c\/td\u003e\r\n\u003ctd\u003eTranscatheter Repair versus Mitral Valve Surgery for Secondary Mitral Regurgitation\u003c\/td\u003e\r\n\u003ctd\u003eVIDEO\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e71\u003c\/td\u003e\r\n\u003ctd\u003eCryptogenic Stroke: What’s a PFO?\u003c\/td\u003e\r\n\u003ctd\u003e08:37\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e72\u003c\/td\u003e\r\n\u003ctd\u003eSurgical vs Transcatheter Approaches in Functional Mitral Regurgitation: Short and Long-Term Data\u003c\/td\u003e\r\n\u003ctd\u003e06:25\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e73\u003c\/td\u003e\r\n\u003ctd\u003eFailure to Cross: Success Begins with Failure\u003c\/td\u003e\r\n\u003ctd\u003e15:16\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e74\u003c\/td\u003e\r\n\u003ctd\u003eLeft Main Disease: Management Challenges and PCI vs CABG Decision-Making\u003c\/td\u003e\r\n\u003ctd\u003e10:22\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e75\u003c\/td\u003e\r\n\u003ctd\u003eMaking the Cath Lab a Safer Environment: Advances in Radiation Safety\u003c\/td\u003e\r\n\u003ctd\u003e12:55\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e76\u003c\/td\u003e\r\n\u003ctd\u003eTop Coronary Trials of the Last Year – 2025 Update\u003c\/td\u003e\r\n\u003ctd\u003e14:09\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e77\u003c\/td\u003e\r\n\u003ctd\u003eOh, How I Wish That Wouldn’t Have Happened\u003c\/td\u003e\r\n\u003ctd\u003e19:03\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e78\u003c\/td\u003e\r\n\u003ctd\u003eWill There Be New Indications for the Use of DCB in Coronary Intervention?\u003c\/td\u003e\r\n\u003ctd\u003e13:22\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e79\u003c\/td\u003e\r\n\u003ctd\u003eCCTA in 2025 – Planning PCI\u003c\/td\u003e\r\n\u003ctd\u003e11:26\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e80\u003c\/td\u003e\r\n\u003ctd\u003eAMI With Cardiogenic Shock and RV Failure: Escalating to ECMO for Hemodynamic Rescue\u003c\/td\u003e\r\n\u003ctd\u003e02:55\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e81\u003c\/td\u003e\r\n\u003ctd\u003eComprehensive Invasive Physiology Suite: From Diagnosis to Outcomes\u003c\/td\u003e\r\n\u003ctd\u003e10:20\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e82\u003c\/td\u003e\r\n\u003ctd\u003eSTEMI vs. Cardiogenic Shock: Understanding the Data on Complete vs. Culprit-Only PCI\u003c\/td\u003e\r\n\u003ctd\u003e13:07\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e83\u003c\/td\u003e\r\n\u003ctd\u003eExpanding Indication for Intravascular Lithotripsy\u003c\/td\u003e\r\n\u003ctd\u003e14:50\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e84\u003c\/td\u003e\r\n\u003ctd\u003eRestore EF, Protect III, Protect IV: Where Is the Data Leading?\u003c\/td\u003e\r\n\u003ctd\u003e09:00\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e85\u003c\/td\u003e\r\n\u003ctd\u003eShock Outcomes in 2024: Review of Recent Data and Where to Go from There\u003c\/td\u003e\r\n\u003ctd\u003e14:45\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e86\u003c\/td\u003e\r\n\u003ctd\u003eAcute Cardiogenic Shock Management\u003c\/td\u003e\r\n\u003ctd\u003e10:17\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e87\u003c\/td\u003e\r\n\u003ctd\u003eSTEMI Management: Unloading Before Revascularization – Clinical Implications\u003c\/td\u003e\r\n\u003ctd\u003e10:53\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e88\u003c\/td\u003e\r\n\u003ctd\u003eElective Multivessel CAD and the Evidence for Complete Revascularization\u003c\/td\u003e\r\n\u003ctd\u003e09:50\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003c\/tbody\u003e\r\n\u003c\/table\u003e\r\n \r\n\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954672504930,"sku":"MED-AMB07938","price":20.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Scottsdale-Interventional-Forum-SIF-2025.webp?v=1779382162","url":"https:\/\/meducourse.com\/products\/scottsdale-interventional-forum-sif-2025","provider":"Meducourse","version":"1.0","type":"link"}